Inventor · disambiguated record
Venkata Ramana Doppalapudi
Also filed as: DOPPALAPUDI VENKATA · DOPPALAPUDI VENKATA R · DOPPALAPUDI VENKATA RAMANA
49 granted patents·25 pending applications·500 citations·filing 1998–2025
98Inventor score
Files withAVIDITY BIOSCIENCES INC54RES CORP TECHNOLOGIES INC5COVX TECHNOLOGIES IRELAND LTD3CELMED ONCOLOGY USA INC2DOPPALAPUDI VENKATA RAMANA2
Top patents by PatentIndex Score
74 records- 0198US12064483B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2022·Granted Aug 20, 2024·19 cites·24 claims
- 0298US11446387B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Sep 20, 2022·8 cites·14 claims
- 0398US11400163B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2021·Granted Aug 2, 2022·26 cites·22 claims
- 0498US11311627B1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2021·Granted Apr 26, 2022·28 cites·24 claims
- 0598US11253607B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 22, 2022·7 cites·23 claims
- 0698US11246941B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 15, 2022·7 cites·23 claims
- 0798US11179472B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2018·Granted Nov 23, 2021·35 cites·25 claims
- 0898US11028179B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Jun 8, 2021·16 cites·20 claims
- 0998US10994020B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2018·Granted May 4, 2021·32 cites·24 claims
- 1098US10913800B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 9, 2021·19 cites·27 claims
- 1198US10881743B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2019·Granted Jan 5, 2021·55 cites·16 claims
- 1298US10787519B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Sep 29, 2020·19 cites·17 claims
- 1398US10550188B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Feb 4, 2020·80 cites·13 claims
- 1497US11707532B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jul 25, 2023·3 cites·14 claims
- 1597US11576980B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 14, 2023·6 cites·23 claims
- 1697US11497814B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Nov 15, 2022·3 cites·30 claims
- 1797US10487149B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Nov 26, 2019·21 cites·18 claims
- 1896US11834510B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Dec 5, 2023·4 cites·20 claims
- 1996US11583591B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 21, 2023·2 cites·14 claims
- 2096US11554176B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jan 17, 2023·2 cites·16 claims
- 2196US11110180B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Sep 7, 2021·19 cites·20 claims
- 2295US12427202B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2023·Granted Sep 30, 2025·1 cites·9 claims
- 2395US10800848B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Oct 13, 2020·7 cites·16 claims
- 2494US11872287B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jan 16, 2024·1 cites·17 claims
- 2593US12006499B2Una amidites and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Jun 11, 2024·2 cites·8 claims
- 2693US11364302B1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jun 21, 2022·2 cites·20 claims
- 2791US2024358736A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2889US12359202B2Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skippingAVIDITY BIOSCIENCES INC·Filed 2024·Granted Jul 15, 2025·1 cites·21 claims
- 2989US12071621B2Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skippingAVIDITY BIOSCIENCES INC·Filed 2023·Granted Aug 27, 2024·1 cites·21 claims
- 3087US7521425B2Anti-angiogenic compoundsCOVX TECHNOLOGIES IRELAND LTD·Filed 2006·Granted Apr 21, 2009·22 cites·12 claims
- 3187US2025381285A1Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3286US12263224B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Apr 1, 2025·0 cites·15 claims
- 3385US2023047754A1Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3484US11578090B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 14, 2023·1 cites·1 claims
- 3584US2025381286A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3683US2024228646A9Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3782US2025296946A1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3881US12365704B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jul 22, 2025·0 cites·13 claims
- 3981US11712478B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Aug 1, 2023·0 cites·13 claims
- 4079US12351637B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jul 8, 2025·0 cites·15 claims
- 4179US12234290B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 25, 2025·0 cites·23 claims
- 4279US8288349B2Anti-angiogenic compoundsBRADSHAW CURT WILLIAM·Filed 2007·Granted Oct 16, 2012·7 cites·29 claims
- 4379US2024301419A1Una amidites and uses thereofAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 4478US7163923B2Peptide deformylase activated prodrugsCELMED ONCOLOGY USA INC·Filed 2002·Granted Jan 16, 2007·10 cites·23 claims
- 4578US6770759B2Penicillanic acid derivative compounds and methods of makingRES CORP TECHNOLOGIES INC·Filed 2002·Granted Aug 3, 2004·7 cites·14 claims
- 4678US2025161344A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4778US2025195676A1Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4878US2025171544A1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4975US2020123261A1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 5074US12364769B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jul 22, 2025·0 cites·12 claims
Showing the top 50 of 74 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →